Hormone therapy is the most effective treatment measured for hot flashes and night sweats, and for vaginal and urinary symptoms local estrogen sits in its own low-risk category. The 2002 result that led many women and doctors to stop hormone therapy was drawn from women mostly in their sixties and well past menopause; re-analyzed by age and by years since the final period, the benefit-to-risk picture is more favorable when it is started near the onset, typically under 60 or within 10 years.
The risks are specific: mainly breast cancer with longer combined use, and blood clots and stroke that run higher with the oral route than the patch. Whether it fits you is a decision made with a clinician, against your own history.
Findings & Outcomes
What It Is
Menopausal hormone therapy replaces the estrogen the ovaries stop making after menopause, and it comes in a few forms that differ in what they treat and in the risks they carry. Systemic estrogen is carried through the whole body, treats hot flashes and night sweats, eases the broken sleep they cause, and protects bone. If you still have a uterus it is given with a progestogen, because estrogen on its own thickens the uterine lining over time and a progestogen prevents most of that. After a hysterectomy the estrogen is given alone, and its risk profile differs from the combined form.
Local vaginal estrogen sits in a category of its own. It is a cream, tablet, ring or gel used in the vagina for dryness, painful sex and recurrent urinary symptoms, the cluster now called the genitourinary syndrome of menopause. Very little reaches the bloodstream, and users show no rise in the cancers or clots that systemic therapy can raise, so it is a separate decision from systemic hormone therapy, open even to many women who cannot take the systemic form.
The route changes the risk. The same hormone can be swallowed as a tablet or absorbed through the skin from a transdermal patch, gel or spray. Swallowed estrogen passes through the liver first, which raises clotting factors; estrogen absorbed through the skin does not, so the blood clot and stroke risk runs higher with the oral tablet than with the patch. For a woman with any added clot risk, the skin route is often chosen for that reason.
Custom-compounded "bioidentical" hormones are sold as a safer, more natural choice, and they are not. FDA-approved bioidentical hormones exist and are regulated. The custom-compounded versions carry no advantage shown over them, with less oversight of dose and purity, and the salivary hormone tests used to tailor a compounded dose do not track a reliable target.
What It Does, and the Balance of Risk
Hormone therapy is the most effective treatment measured for hot flashes and night sweats, cutting them by about 75% against a dummy treatment, the largest effect measured for any treatment of these symptoms. Local vaginal estrogen reliably relieves vaginal dryness and painful sex. Combined therapy protects bone, cutting total fractures by about a quarter (hazard ratio 0.76) and hip fractures by a third. These are its clearest benefits.
In absolute numbers the risks are small, weighed against the symptom relief and bone protection the therapy provides.
The breast cancer signal is mainly attached to the combined estrogen-plus-progestogen form and grows with the years of use. Five years started at age 50 adds roughly one extra breast cancer per 50 users of estrogen with daily progestogen, against about one per 200 for estrogen alone, counted across ages 50 to 69. Blood clots run higher with the oral tablet (odds ratio 1.58) and not with the transdermal patch, gel or spray (0.93). Stroke follows the same split: raised by oral tablets and by high-dose patches, not by low-dose patches.
Two more risks were measured only in specific groups. Women who first started combined therapy at 65 or older had about twice the rate of dementia, roughly 23 extra cases per 10,000 women each year. This is a late-start finding, and it does not carry over to a woman starting near menopause for symptoms. Using hormone therapy also raised ovarian cancer by about a third, which works out to about one extra case per 1,000 women who use it for five years from around age 50, from pooled observational data.
Women on combined therapy developed diabetes about a fifth less often than on placebo over the trial, 3.5% against 4.2%. This is a measured effect. It is still not a reason to prescribe hormone therapy, which is given for symptoms and weighed against the risks above, not to prevent diabetes.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Menopause And Vasomotor
Hot flashes about 75% fewer on hormone therapy than placebo, the largest effect measured
Hormone therapy cuts hot flashes and night sweats more than anything else that has been tested, roughly three-quarters fewer than a dummy treatment.
Pooled across randomized trials, oral estrogen and combined estrogen-progestogen therapy reduced the frequency of hot flashes by about 75% against placebo, with a large reduction in severity as well. It is the largest effect measured for vasomotor symptoms. Measured in: Postmenopausal women with vasomotor symptoms across randomized placebo-controlled trials. Placebo alone reduces hot flashes substantially in these trials, so the true drug effect is the gap above a large placebo response rather than the raw reduction. Trial durations were mostly short.
Who this may not transfer to:Menopausal hormone therapy is given to women for symptoms of the menopause transition; these findings are not intended to apply to men.
The study · 1
MacLennan et al., oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes · Cochrane Database Syst Rev 2004
A progestogen prevents most of the uterine-lining thickening unopposed estrogen causes
In women who still have a womb, estrogen on its own thickens the lining, and adding a progestogen prevents most of that.
Unopposed estrogen raised endometrial hyperplasia in a dose- and duration-dependent way in postmenopausal women with a uterus. Adding a progestogen, continuously or sequentially, reduced that excess, with continuous combined regimens giving the most reliable protection; sequential progestogen over more than 5 years still carried some increased hyperplasia risk. Measured in: Postmenopausal women with an intact uterus across 46 randomized trials. The endpoint is endometrial hyperplasia and bleeding rather than endometrial cancer directly, and the degree of protection depended on the progestogen regimen and how long it was used.
Who this may not transfer to:Endometrial protection applies to women with a uterus; it is not applicable to men.
The study · 1
Furness et al., hormone therapy in postmenopausal women and risk of endometrial hyperplasia · Cochrane Database Syst Rev 2012
Fezolinetant and elinzanetant cut hot flashes by about 2 to 2.5 more a day than placebo
New non-hormonal drugs that block a brain signal, fezolinetant and elinzanetant, cut hot flashes by a couple more per day than a dummy pill.
Fezolinetant, a neurokinin-3 receptor antagonist, reduced the frequency of moderate-to-severe hot flashes by about 2 to 2.5 more per day than placebo over 12 weeks, with a matching drop in severity. The dual neurokinin-1 and 3 antagonist elinzanetant reduced them similarly in the OASIS trials. Neither is a hormone. Measured in: Roughly 500 women per pivotal trial with moderate-to-severe vasomotor symptoms, plus the OASIS elinzanetant trials. These are short trials against placebo rather than head-to-head against hormone therapy, so the size of the benefit sits below estrogen's. Fezolinetant carries a liver-monitoring requirement, and long-term safety is still accruing.
Who this may not transfer to:These drugs were trialled in women with menopausal vasomotor symptoms; the findings are not intended to apply to men.
The studies · 2
Lederman et al., fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1) · Lancet 2023
SSRIs, SNRIs, gabapentin and clonidine cut hot flashes by about 1 to 2 more a day than placebo
Some antidepressants, along with gabapentin and clonidine, ease hot flashes by a modest amount, less than hormones, and an option when hormones are not wanted.
SSRIs and SNRIs, gabapentin and clonidine each reduced the frequency and severity of hot flashes more than placebo, with effects smaller than estrogen. Antidepressants and clonidine reduced daily flashes by roughly 1 to 2 more than placebo, and gabapentin by a similar amount. Measured in: Postmenopausal women across 43 randomized and controlled trials of non-hormonal drugs. Trials were mostly short and some included women being treated for breast cancer, so effect sizes vary by drug and population. Paroxetine and fluoxetine can blunt tamoxifen, which matters for women on it.
Who this may not transfer to:These treatments were studied for menopausal hot flushes in women; the findings are not intended to apply to men.
The study · 1
Nelson et al., nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis · JAMA 2006
Cognitive behavioral therapy lowers how much hot flashes bother you, not how often they come
A short course of cognitive behavioral therapy makes hot flashes bother you less, even if it does not lower how often they come.
Group and self-help cognitive behavioral therapy reduced how much hot flashes and night sweats bothered women, with a moderate-to-large effect on the problem rating that held at follow-up. It worked in women having flashes after breast cancer treatment, where hormones are usually avoided. Measured in: Menopausal women in two randomized trials, including one in women who had had breast cancer. The main change is in the distress and interference from flashes rather than in their frequency, and outcomes were self-reported, so the benefit is different in kind from a drug that cuts the count.
Who this may not transfer to:These trials enrolled menopausal women; the findings are not intended to apply to men.
The studies · 2
Ayers et al., effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2) · Menopause 2012
Mann et al., cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1) · Lancet Oncol 2012
Longevity And Mortality
No difference in death over 18 years (hazard ratio 0.99)
Over 18 years, women who had taken hormone therapy in the trials were no more or less likely to have died than those who took placebo.
Across a cumulative 18 years of follow-up, all-cause mortality did not differ from placebo, hazard ratio 0.99 (95% CI 0.94 to 1.03) in the pooled cohort, 1.02 for combined therapy and 0.94 for estrogen alone. Neither cancer nor cardiovascular mortality was significantly raised. Measured in: 27,347 postmenopausal women across both Women's Health Initiative trials, 18-year cumulative follow-up. Mortality is a coarse endpoint that can hide benefit in one cause offsetting harm in another. The trials tested oral formulations begun largely in older women, so this neutral mortality result does not by itself settle the risk for a woman starting near menopause.
Who this may not transfer to:Mortality was measured in women in the hormone therapy trials; it is not intended to apply to men.
The study · 1
Genitourinary
Vaginal estrogen relieves dryness and painful sex, odds ratios 4 to 13 across 30 trials
Estrogen used in the vagina reliably relieves dryness and painful sex, and the cream, tablet and ring forms work about equally well.
Across 30 randomized trials and 6,235 women, intravaginal estrogen improved symptoms against placebo, with odds ratios between 4.10 and 12.67 depending on preparation. Creams, tablets and rings did not differ from each other in effect. Measured in: 6,235 postmenopausal women with vaginal atrophy. Most trials ran 12 weeks or less, so long-term safety rests on observational data rather than on these trials. Many were manufacturer-funded, and the outcome measures for dryness and discomfort varied enough that pooling them is approximate.
Who this may not transfer to:Vaginal oestrogen for genitourinary symptoms applies to women; it is not applicable to men.
The study · 1
Lethaby et al., local oestrogen for vaginal atrophy in postmenopausal women · Cochrane Database Syst Rev 2016
Bone Density
Combined hormone therapy cut total fractures by about 24% (hazard ratio 0.76)
Combined hormone therapy cut fractures by about a quarter and strengthened bone at the hip and spine.
Combined estrogen-progestin lowered total fractures, hazard ratio 0.76, about 24% fewer, and hip fractures, hazard ratio 0.67. Bone mineral density rose at the hip and spine over the trial. This was the first randomized proof that hormone therapy prevents fractures in unselected women. Measured in: 16,608 postmenopausal women aged 50 to 79 with an intact uterus. The women were not selected for low bone density, so the number of fractures prevented is set against the other risks of combined therapy rather than read on its own. Bone loss resumes after therapy stops.
Who this may not transfer to:Fracture reduction was measured in postmenopausal women on hormone therapy; it is not intended to apply to men.
The study · 1
Heart And Vascular
Artery-wall thickening slowed only when estrogen started within 6 years of menopause
Estrogen slowed the thickening of an artery wall in women who started soon after menopause, but not in those who started 10 or more years later.
In women less than 6 years past menopause, carotid intima-media thickness rose 0.0044 mm per year on oral estradiol against 0.0078 on placebo (P=0.008). In women 10 or more years past, 0.0100 against 0.0088 (P=0.29). Interaction P=0.007. Measured in: 643 healthy postmenopausal women, stratified by time since menopause. Carotid wall thickness is a surrogate marker. The trial was not powered for heart attacks or strokes and did not measure them as endpoints, so this shows a difference in a marker rather than in events. Participants were healthy volunteers.
Who this may not transfer to:Measured in postmenopausal women; the finding is not intended to apply to men.
The study · 1
Hodis et al., vascular effects of early versus late postmenopausal treatment with estradiol (ELITE) · N Engl J Med 2016
Blood Sugar
New diabetes about a fifth lower on combined therapy, 3.5% against 4.2%
Women taking combined hormone therapy were about a fifth less likely to develop diabetes over the trial than those on placebo.
Over 5.6 years, women on combined conjugated equine estrogen with medroxyprogesterone acetate developed treated diabetes less often than on placebo, cumulative incidence 3.5% against 4.2%, hazard ratio 0.79 (95% CI 0.67 to 0.93, P=0.004). The reduction held after accounting for changes in body weight and waist circumference. Measured in: 15,641 postmenopausal women aged 50 to 79 with an intact uterus in the Women's Health Initiative Hormone Trial, mean 5.6 years of follow-up. Diabetes was a secondary finding measured by whether treatment was started, not a target the trial was designed to test, and hormone therapy is not given to prevent diabetes. The effect was seen for the oral combined formulation and sits alongside the trial's other risks.
Who this may not transfer to:The diabetes finding was measured in postmenopausal women on hormone therapy; it is not intended to apply to men.
The study · 1
Margolis et al., effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial · Diabetologia 2004
The Timing of When You Start
The 2002 result was drawn from women who were mostly in their sixties and more than a decade past their final period. Re-read by age and by years since menopause, the balance is more favorable when therapy begins near the onset. In the pooled Women's Health Initiative analyses, outcomes were better for women who started aged 50 to 59 or within 10 years of menopause than for women who started at 70 to 79 or more than 20 years past it, the pattern people call the timing hypothesis. A separate trial that tracked an artery wall found estrogen slowed its thickening in women who started within 6 years of menopause (0.0044 against 0.0078 mm a year) but not in those who started 10 or more years later.
The late-start findings point the same way. The doubled dementia rate was seen only in women who first took combined therapy at 65 or older. Starting systemic hormone therapy many years after menopause mainly to protect the heart is not supported, because the early-start vascular picture does not carry over to a late start. Over 18 years of follow-up, women who had taken hormone therapy in the trials were no more or less likely to have died than those who took placebo (hazard ratio 0.99), so the decision turns on symptoms and the specific risks, not on living longer or shorter overall.
Non-Hormonal Options
For women who cannot take hormones or prefer not to, several non-hormonal treatments have trial support, each weaker than estrogen for hot flashes:
- Neurokinin-receptor antagonists (fezolinetant and elinzanetant), the newest, block a brain signal involved in hot flashes and cut them by about 2 to 2.5 more per day than a dummy pill.
- Low-dose SSRIs and SNRIs, gabapentin, and clonidine each ease hot flashes by a smaller amount, about 1 to 2 more per day than placebo.
- A short course of cognitive behavioral therapy lowers how much hot flashes bother you without changing how often they come, and it worked in women having flashes after breast cancer.
The ordinary basics pair with any of these, and with a hormone decision or in place of one:
- Strength training builds bone in the years the loss concentrates.
- A cooler room and lighter bedding work against the night sweats directly.
- Regular activity supports the heart and the mood changes of the transition.
None of these cuts the hot flashes the way hormones do, and each helps on its own at little or no cost.
Go Deeper
The women's-section pages sit alongside this one, and the basics that pair with any hormone decision have their own pages.
- Menopause and Hot Flashes: the transition itself, the symptoms, and the botanicals people reach for.
- Perimenopause: the run-up, when cycles and symptoms first change.
- PMS: the cyclical picture earlier in life.
The Chinese Medicine View
The Chinese Medicine View
Chinese medicine has nothing to say about a manufactured hormone, and it reads the transition the therapy is given for as the Kidneys emptying with age. The cooling, moistening Yin depletes first, so the warmth it was holding rises as empty heat, the heat of depletion rather than excess. Which pattern fits points to what the tradition would support, and it treats by nourishing the Yin, not by cooling alone. This is an interpretive lens on the transition, not a comment on hormone therapy and not a claim that one predicts the other. A practitioner reads the pulse and tongue a page cannot, and the tradition does not hold that every woman in this season needs the same support.
The central picture: hot flashes rising to the face and chest, night sweats that come in sleep and stop on waking, heat in the palms and soles, dry mouth and eyes, vaginal dryness, weak low back and knees. The tradition points here toward nourishing Yin, the Liu Wei Di Huang and Zhi Bai Di Huang families.
Flashes and sweating together with cold feet, aversion to cold, low libido and exhaustion. Common in the transition, and what Er Xian Tang was built for, warming Yang tonics paired with fire-draining herbs in the one prescription.
The same Yin depletion with the Shen unsettled by it: waking at two or three, palpitations, anxiety with no object, a mind that will not stop, vivid dreams. Tian Wang Bu Xin Dan is the classical answer.
Cautions
Extra restraintEverything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Oral estrogen plus progestin (2002): about 7 to 8 more heart events, strokes, clots and breast cancers per 10,000 women a year, and 5 fewer hip fractures
Per 10,000 women per year: 7 more coronary events, 8 more strokes, 8 more pulmonary emboli and 8 more invasive breast cancers, against 6 fewer colorectal cancers and 5 fewer hip fractures. Hazard ratios 1.29 for coronary heart disease, 1.41 stroke, 2.13 pulmonary embolism, 1.26 breast cancer. Mean age at entry was 63 and most participants were more than a decade past their final period, which is not the woman who asks about hormone therapy for symptoms. One oral formulation was tested, conjugated equine estrogen with medroxyprogesterone acetate. The breast cancer confidence interval touched 1.00.Rossouw et al., risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial
Estrogen alone after hysterectomy: breast cancer not raised (HR 0.77), stroke higher (HR 1.39)
In women with a prior hysterectomy taking conjugated equine estrogen alone, the breast cancer hazard ratio was 0.77 (95% CI 0.59 to 1.01), so not raised and possibly lowered. Coronary heart disease was 0.91, stroke 1.39 (1.10 to 1.77), and hip fracture 0.61. This estrogen-alone result disagrees with the observational finding of a smaller breast cancer excess for estrogen alone, and stroke was raised, so 'different profile' does not mean 'no risk'. One oral formulation was tested.Anderson et al., effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial
Combined therapy adds about one breast cancer per 50 users over five years, one per 200 for estrogen alone
Five years of therapy started at age 50 adds roughly one breast cancer per 50 users of estrogen with daily progestogen, one per 70 with intermittent progestogen, and one per 200 with estrogen alone, counted across ages 50 to 69. Ten years is about twice that. Relative risk in current users of 5 to 14 years: 2.08 for estrogen-progestogen, 1.33 for estrogen alone. Individual participant data pooled from prospective observational studies, not from randomized trials, and the direction for estrogen alone disagrees with the trial of estrogen alone. Vaginal estrogens showed no excess. Some excess persisted more than a decade after stopping.Collaborative Group on Hormonal Factors in Breast Cancer, type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence
Hormone therapy outcomes more favorable started at 50 to 59 than at 70 to 79
In the pooled Women's Health Initiative analyzes, results were more favorable in women who started therapy aged 50 to 59, or within 10 years of menopause, than in women aged 70 to 79 or more than 20 years past it. The absolute excess of adverse events was concentrated in the older, later-starting women, and for several outcomes there was a significant trend across age. These are subgroup analyzes stratified after the fact, not the trials' primary comparison, so the age-and-timing reading is hypothesis-generating rather than a result the trials were designed to prove. The trials tested oral formulations only.Manson et al., menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials
Blood clots raised by oral hormones (OR 1.58), not by patches, gels or sprays (0.93)
Oral hormone therapy was associated with venous thromboembolism, adjusted odds ratio 1.58 (95% CI 1.52 to 1.64); oral estrogen alone 1.40, oral combined preparations 1.73. Transdermal preparations showed no increase, 0.93 (0.87 to 1.01). Nested case-control drawn from prescribing records, so exposure is what was dispensed rather than what was taken. Route was not randomized, and no trial has randomized oral against transdermal with clot as the endpoint.Vinogradova et al., use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
Stroke raised by oral hormones (RR 1.28) and high-dose patches, not by low-dose patches
Oral hormone therapy was associated with stroke, rate ratio 1.28 (95% CI 1.15 to 1.42). Low-dose transdermal patches of 50 micrograms or less were not, 0.81 (0.62 to 1.05). Higher-dose patches were, 1.89 (1.15 to 3.11). Nested case-control from prescribing records, so exposure is what was dispensed. Route and dose were not randomized, and this shows an association rather than a tested causal difference.Renoux et al., transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study
Vaginal estrogen users show no rise in breast or endometrial cancer, stroke or clots over 7.2 years
Over a median 7.2 years, women using vaginal estrogen showed no increase in invasive breast cancer, endometrial cancer, colorectal cancer, stroke, pulmonary embolism, deep vein thrombosis or hip fracture compared with non-users. Risks were similar with and without a uterus. Observational rather than randomized, and the number of vaginal estrogen users was modest, so this supports the low-risk reading of local estrogen without proving it to a trial standard. Endometrial safety over many years still depends on watching for bleeding.Crandall et al., breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study
Custom-compounded bioidentical hormones show no advantage over approved products
An Endocrine Society scientific statement found custom-compounded bioidentical hormones show no advantage over approved products in safety or effectiveness, that compounded preparations lack the standardization, purity testing and safety monitoring of regulated ones, and that salivary hormone testing used to tailor them does not track a reliable target. FDA-approved bioidentical formulations exist and are regulated. This is a scientific statement synthesizing the literature rather than a head-to-head trial, and it addresses the compounded, custom-mixed products specifically, not the regulated bioidentical formulations that carry the same oversight as any approved drug.Santoro et al., compounded bioidentical hormones in endocrinology practice: an Endocrine Society scientific statement
Combined therapy begun after 65 doubled dementia rate, 23 extra cases per 10,000 women a year
In women aged 65 and older, combined conjugated equine estrogen with medroxyprogesterone acetate raised the rate of probable dementia against placebo, hazard ratio 2.05 (95% CI 1.21 to 3.48, P=0.01), which worked out to about 23 extra cases per 10,000 women per year (45 against 22 per 10,000 person-years, 40 cases against 21). Mild cognitive impairment was not significantly changed, hazard ratio 1.07 (95% CI 0.74 to 1.55). Every woman here began therapy at 65 or older and started the oral combined formulation, so the result speaks to late initiation and does not carry over to a woman who starts near menopause for symptoms. Trials that began therapy soon after menopause, KEEPS-Cog and the WHIMSY substudy, found no such effect on cognition. This is one trial and the dementia case numbers were modest.Shumaker et al., estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study (WHIMS)
Ovarian cancer about a third higher in users, one extra case per 1,000 over five years
In the prospective data pooled across these studies, current or recent hormone therapy use carried a higher rate of ovarian cancer, relative risk 1.37 (95% CI 1.29 to 1.46), rising to 1.53 for serous tumors and 1.42 for endometrioid tumors. For a woman using therapy for 5 years from around age 50, this works out to about one extra ovarian cancer per 1,000 users and about one extra ovarian cancer death per 1,700 users. The excess appeared even with under 5 years of use, relative risk 1.43. The pooled evidence is observational, not randomized, and the absolute risk is small, about one extra case per 1,000 five-year users. The excess was largest for the serous and endometrioid subtypes and diminished the longer ago therapy had stopped.Collaborative Group on Epidemiological Studies of Ovarian Cancer, menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
When to See Someone
Hormone therapy is an individualized decision, and one rule sits above the rest: do not start or stop a prescribed hormone because of anything on this page. These are the signs to see a doctor about, and urgently for the ones marked so:
- Any vaginal bleeding a year or more after your last period, and any unscheduled bleeding on hormone therapy outside an expected withdrawal bleed. Every episode is worth investigating, and spotting counts.
- A new breast lump, a nipple change, or a change in the skin of the breast.
- Sudden swelling, pain or warmth in one leg, chest pain or breathlessness, which can signal a blood clot and need same-day assessment.(seek urgent care)
- A sudden severe headache, weakness or numbness on one side, trouble speaking, or a sudden change in vision, which are stroke warning signs.(seek urgent care)
- A history of breast or other hormone-sensitive cancer, a previous blood clot or stroke, or active liver disease, which are reasons to discuss the decision carefully before starting rather than signs to act on alone.
- New pelvic pain that is persistent, or that is new for you.
- Persistent low mood, loss of interest, or thoughts of harming yourself.(seek urgent care)
This is a reference and learning resource, not medical advice and not a substitute for the clinician who knows your history. Hormone therapy helps a great many women, and whether it fits you depends on your own symptoms, your history and your preferences. That conversation, and any change to a prescribed hormone, belongs with the person who prescribes it.
Common Questions
Is hormone therapy safe?
For most women who start it near menopause, the benefit-to-risk balance is favorable, and that is the framing the current evidence supports. The 2002 headline was drawn from women mostly in their sixties, more than a decade past their final period, and it read worse than the risk for a woman starting under 60 or within 10 years. The risks are specific: mainly breast cancer with longer combined use, and blood clots and stroke that run higher with the oral tablet than with a skin patch. Whether it fits you is a decision made with a clinician against your own history.
What are the actual risks, in plain numbers?
Five years of combined estrogen and daily progestogen started at age 50 adds about one extra breast cancer per 50 users, against about one per 200 for estrogen alone. Blood clots run higher with the oral tablet and not with the patch, gel or spray. Ovarian cancer is raised by about a third, roughly one extra case per 1,000 women over five years of use. Dementia was raised in women who first started combined therapy at 65 or older, and that late-start finding does not carry over to a woman starting near menopause.
Is the patch safer than the pill?
For blood clots and stroke, the evidence points that way. Swallowed estrogen passes through the liver first, which raises clotting factors, so the oral tablet carried a higher clot risk (odds ratio 1.58) while the transdermal patch, gel or spray did not (0.93). Stroke followed the same pattern. For a woman with any added clot risk, the skin route is often chosen for that reason. Both routes treat the hot flashes and protect bone about equally.
What about bioidentical hormones?
FDA-approved bioidentical hormones exist and are regulated, and they are a reasonable option. The custom-compounded "bioidentical" preparations sold as safer or more natural are the ones to be wary of: they carry no advantage shown over the approved products, with less oversight of dose and purity, and the saliva hormone tests used to set a compounded dose do not track a reliable target.
I cannot take hormones. What else works?
Several non-hormonal treatments help, all weaker than estrogen for hot flashes. The neurokinin-receptor antagonists fezolinetant and elinzanetant cut hot flashes by about 2 to 2.5 more per day than a dummy pill. Low-dose SSRIs and SNRIs, gabapentin and clonidine each ease them by about 1 to 2 more per day. A short course of cognitive behavioral therapy lowers how much the flashes bother you. For vaginal dryness and painful sex, local vaginal estrogen sits in its own low-risk category and is often an option even when systemic therapy is not.
Does it protect the heart or help me live longer?
Not as a reason to take it. Started near menopause the vascular picture is favorable, and started late it is not, but over 18 years of follow-up women who took hormone therapy in the trials were no more or less likely to have died than those on placebo. So the decision rests on symptoms and the specific risks, not on heart protection or a longer life. The diabetes finding, about a fifth less new diabetes on combined therapy, is a measured effect and still not a reason to prescribe it.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 22 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.